Business
Sareum : Half-yearly Results to Dec 2024
Sareum : Half-yearly Results to Dec
About this update from Sareum Holdings Plc
[{"type":"text","content":"Sareum Holdings PLC\n (\"Sareum\" or the \"Company\")\n Half-Year Report for the Six Months Ended 31 December 2024\n Cambridge, UK, 25 March 2025 - Sareum Holdings plc (AIM: SAR), a biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer, announces its unaudited results for the six months ended 31 December 2024.\n Sareum also provides a broader update on its operational activities and pipeline progress.\n OPERATIONAL HIGHLIGHTS - INCLUDING POST-PERIOD UPDATES\n SDC-1801 (autoimmune disease)\n SDC-1801 is a TYK2/JAK1 inhibitor being developed as a potential new therapeutic for a range of autoimmune diseases with an initial focus on psoriasis, an autoimmune condition affecting the skin.\n • Successfully completed Phase 1 clinical trial for SDC-1801 with single ascending dose (\"SAD\"), multiple ascending dose (\"MAD\") and food effect studies.\n • SDC-1801 achieved blood plasma levels significantly exceeding predicted therapeutic exposure with a half-life of 17-20 hours, confirming the potential for once-daily dosing. Significant dose-responsive biomarker effects were observed.\n • No deaths or serious adverse events due to SDC-1801 were reported, with frequency of adverse events (all mild or moderate) similar in active and placebo groups.\n • The Clinical Study Report was received in December 2024.\n • Strengthened intellectual property position with:\n o US Patent and Trademark Office granted a patent (US Patent No. 12,187,716) on SDC-1801's chemical structure, its use in treating inflammatory diseases, and certain methods of chemical synthesis.\n o Patent allowance in China protecting certain crystalline forms of SDC-1801 and methods of their preparation with a similar Decision to Grant that was recently received from the Japanese Patent Office.\n SRA737 (cancer)\n SRA737 is a clinical-stage oral, selective Checkpoint kinase 1 inhibitor that targets cancer cell replication and DNA damage repair mechanisms.\n • After the period end, Sareum successfully acquired the licence for SRA737 following the termination of a licensing agreement between CRT Pioneer Fund (\"CPF\") and a US-based licensee in December 2024.\n • Sareum renegotiated significantly improved economic terms, securing 63.5% of all future revenues compared to 27.5% under the former agreement.\n • SRA737 has completed two ph...